The US Food and Drug Administration recently extended the comment period on a controversial draft guidance document that would recommend stronger patient safety guidelines for Laser-Assisted In-Situ Keratomileusis (LASIK) surgery, but plenty of stakeholders from all sides of the issue have already had their say.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?